Do analysts rate ORMP or DRUG?

Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 112.77%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86

Is ORMP or DRUG more profitable?

Oramed Pharmaceuticals' return on equity of -5.37% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.37% -4.83% Bright Minds Biosciences N/A -20.58% -20.25%

Does the media favor ORMP or DRUG?

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.74 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Bright Minds Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ORMP or PRME?

Prime Medicine has a consensus target price of $7.53, suggesting a potential upside of 94.61%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Prime Medicine 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Do analysts recommend GYRE or ORMP?

Gyre Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 131.61%. Given Gyre Therapeutics' higher possible upside, equities research analysts plainly believe Gyre Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend AQST or ORMP?

Aquestive Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 103.35%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aquestive Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer DNA or ORMP?

Ginkgo Bioworks presently has a consensus target price of $8.50, indicating a potential downside of 17.99%. Given Ginkgo Bioworks' higher probable upside, research analysts plainly believe Ginkgo Bioworks is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Oramed Pharmaceuticals (ORMP) Competitors

$4.60 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.60 0.00 (-0.11%)

As of 07/2/2026 05:37 PM Eastern

Compare

ORMP vs. DRUG, PRME, GYRE, AQST, and DNA

Should you buy Oramed Pharmaceuticals stock or one of its competitors? MarketBeat compares Oramed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oramed Pharmaceuticals include Bright Minds Biosciences (DRUG), Prime Medicine (PRME), Gyre Therapeutics (GYRE), Aquestive Therapeutics (AQST), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

How does Oramed Pharmaceuticals compare to Bright Minds Biosciences?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oramed Pharmaceuticals has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	94.14	$64.05M	$2.59	1.78
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 112.77%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Oramed Pharmaceuticals' return on equity of -5.37% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.74 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Bright Minds Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.34, meaning that its share price is 634% less volatile than the broader market.

Summary

Oramed Pharmaceuticals beats Bright Minds Biosciences on 8 of the 14 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Prime Medicine?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Oramed Pharmaceuticals has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oramed Pharmaceuticals has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Oramed Pharmaceuticals' return on equity of -5.37% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Prime Medicine has a consensus target price of $7.53, suggesting a potential upside of 94.61%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Prime Medicine had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 8 mentions for Prime Medicine and 5 mentions for Oramed Pharmaceuticals. Prime Medicine's average media sentiment score of 1.00 beat Oramed Pharmaceuticals' score of -0.74 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Negative
Prime Medicine	Positive

Oramed Pharmaceuticals has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	94.14	$64.05M	$2.59	1.78
Prime Medicine	$4.63M	150.97	-$201.14M	-$1.23	N/A

Summary

Prime Medicine beats Oramed Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Gyre Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 131.61%. Given Gyre Therapeutics' higher possible upside, equities research analysts plainly believe Gyre Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

In the previous week, Oramed Pharmaceuticals had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.74 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Neutral
Oramed Pharmaceuticals	Negative

Oramed Pharmaceuticals has lower revenue, but higher earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$117.05M	6.99	$5.03M	-$0.09	N/A
Oramed Pharmaceuticals	$2M	94.14	$64.05M	$2.59	1.78

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Gyre Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Summary

Gyre Therapeutics beats Oramed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oramed Pharmaceuticals has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.78	-$83.78M	-$0.61	N/A
Oramed Pharmaceuticals	$2M	94.14	$64.05M	$2.59	1.78

Oramed Pharmaceuticals has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

In the previous week, Oramed Pharmaceuticals had 5 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 0 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.74 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aquestive Therapeutics	Neutral
Oramed Pharmaceuticals	Negative

Aquestive Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 103.35%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aquestive Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aquestive Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Summary

Aquestive Therapeutics beats Oramed Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ginkgo Bioworks presently has a consensus target price of $8.50, indicating a potential downside of 17.99%. Given Ginkgo Bioworks' higher probable upside, research analysts plainly believe Ginkgo Bioworks is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Oramed Pharmaceuticals had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 0 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.74 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
Oramed Pharmaceuticals	Negative

Oramed Pharmaceuticals has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Oramed Pharmaceuticals' return on equity of -5.37% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

Oramed Pharmaceuticals has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.98	-$312.76M	-$5.36	N/A
Oramed Pharmaceuticals	$2M	94.14	$64.05M	$2.59	1.78

Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Summary

Oramed Pharmaceuticals beats Ginkgo Bioworks on 10 of the 16 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORMP vs. The Competition

Export

Metric	Oramed Pharmaceuticals	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$188.26M	$8.77B	$7.18B	$12.47B
Dividend Yield	5.43%	2.45%	2.66%	6.50%
P/E Ratio	1.78	16.55	28.02	24.70
Price / Sales	94.14	6.93	532.59	97.92
Price / Cash	50.70	18.11	49.26	57.09
Price / Book	0.92	3.53	10.96	6.46
Net Income	$64.05M	$226.25M	$3.57B	$337.01M
7 Day Performance	-1.50%	1.50%	2.12%	1.69%
1 Month Performance	23.99%	-0.23%	5.25%	3.81%
1 Year Performance	110.62%	-0.49%	33.29%	23.90%

Oramed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORMP Oramed Pharmaceuticals	2.5322 of 5 stars	$4.60 flat	N/A	+110.6%	$188.26M	$2M	1.78	10	News Coverage Insider Trade Gap Up
DRUG Bright Minds Biosciences	2.1522 of 5 stars	$65.13 +2.6%	$143.83 +120.8%	+138.9%	$617.90M	N/A	N/A	N/A	News Coverage Analyst Upgrade
PRME Prime Medicine	2.9318 of 5 stars	$3.24 -3.9%	$7.38 +127.6%	N/A	$608.68M	$4.63M	N/A	N/A	Positive News Analyst Revision
GYRE Gyre Therapeutics	1.7917 of 5 stars	$6.13 flat	$17.00 +177.3%	-9.8%	$594.78M	$116.59M	N/A	40	News Coverage Positive News
AQST Aquestive Therapeutics	2.4449 of 5 stars	$5.03 +6.6%	$8.50 +69.0%	+12.4%	$592.12M	$44.54M	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORMP) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. DRUG, PRME, GYRE, AQST, and DNA

How does Oramed Pharmaceuticals compare to Bright Minds Biosciences?

Summary

How does Oramed Pharmaceuticals compare to Prime Medicine?

Summary

How does Oramed Pharmaceuticals compare to Gyre Therapeutics?

Summary

How does Oramed Pharmaceuticals compare to Aquestive Therapeutics?

Summary

How does Oramed Pharmaceuticals compare to Ginkgo Bioworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. DRUG, PRME, GYRE, AQST, and DNA

How does Oramed Pharmaceuticals compare to Bright Minds Biosciences?

Do insiders & institutionals have more ownership in ORMP or DRUG?

Which has preferable earnings and valuation, ORMP or DRUG?

Do analysts rate ORMP or DRUG?

Is ORMP or DRUG more profitable?

Does the media favor ORMP or DRUG?

Which has more risk & volatility, ORMP or DRUG?

Summary

How does Oramed Pharmaceuticals compare to Prime Medicine?

Which has more risk & volatility, ORMP or PRME?

Do insiders and institutionals hold more shares of ORMP or PRME?

Is ORMP or PRME more profitable?

Do analysts prefer ORMP or PRME?

Does the media favor ORMP or PRME?

Which has stronger valuation and earnings, ORMP or PRME?

Summary

How does Oramed Pharmaceuticals compare to Gyre Therapeutics?

Do analysts recommend GYRE or ORMP?

Is GYRE or ORMP more profitable?

Does the media refer more to GYRE or ORMP?

Which has preferable valuation & earnings, GYRE or ORMP?

Do insiders & institutionals have more ownership in GYRE or ORMP?

Which has more risk & volatility, GYRE or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Aquestive Therapeutics?

Do insiders and institutionals have more ownership in AQST or ORMP?

Which has stronger valuation and earnings, AQST or ORMP?

Is AQST or ORMP more profitable?

Does the media refer more to AQST or ORMP?

Do analysts recommend AQST or ORMP?

Which has more volatility & risk, AQST or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Ginkgo Bioworks?

Do insiders & institutionals have more ownership in DNA or ORMP?

Do analysts prefer DNA or ORMP?

Does the media refer more to DNA or ORMP?

Is DNA or ORMP more profitable?

Which has stronger valuation & earnings, DNA or ORMP?

Which has more volatility & risk, DNA or ORMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools